HEALTHSTAT NEWS
STAT+: Is there a pharma mega-merger in the making?
The article discusses the FDA's upcoming decision on Moderna's mRNA flu shot, a renewed debate over 340B rebates, and legal challenges regarding Lilly's insulin pricing. It highlights key developments in the biotech and pharmaceutical sectors.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about an FDA review of Moderna’s flu shot, J&J’s focus on cancer, and more
- STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
- STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
- STAT+: Four major biotech updates to catch up on
- STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more